Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2025(Status and Outlook)
Description
Report Overview
The market for targeted EGFR receptor tyrosine kinase (RTK) inhibitors in non-small cell lung cancer (NSCLC) is a specialized segment of oncology therapeutics focused on precision medicine. These inhibitors, such as gefitinib, erlotinib, afatinib, and osimertinib, selectively block the epidermal growth factor receptor (EGFR), a key driver of tumor proliferation in EGFR-mutant NSCLC. The market has grown significantly due to advancements in biomarker testing and the development of next-generation inhibitors that overcome resistance mutations. Demand is driven by the high prevalence of EGFR mutations in NSCLC, particularly in Asian populations, and the shift toward personalized treatment over conventional chemotherapy. Key players include AstraZeneca, Roche, and Boehringer Ingelheim, with ongoing R&D focused on improving efficacy and addressing acquired resistance. Pricing, reimbursement policies, and competition from immuno-oncology agents like PD-1/PD-L1 inhibitors influence market dynamics. Emerging markets in Asia-Pacific show rapid growth due to increasing diagnosis rates and healthcare investment, while North America and Europe remain dominant in innovation and adoption.
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market size was estimated at USD 6439.0 million in 2024, exhibiting a CAGR of 8.50% during the forecast period.
This report provides a deep insight into the global Targeted Drug EGFR RTK Inhibitors for NSCLC market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drug EGFR RTK Inhibitors for NSCLC market in any manner.
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Market Segmentation (by Type)
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Others
Market Segmentation (by Application)
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market
Overview of the regional outlook of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Targeted Drug EGFR RTK Inhibitors for NSCLC, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
The market for targeted EGFR receptor tyrosine kinase (RTK) inhibitors in non-small cell lung cancer (NSCLC) is a specialized segment of oncology therapeutics focused on precision medicine. These inhibitors, such as gefitinib, erlotinib, afatinib, and osimertinib, selectively block the epidermal growth factor receptor (EGFR), a key driver of tumor proliferation in EGFR-mutant NSCLC. The market has grown significantly due to advancements in biomarker testing and the development of next-generation inhibitors that overcome resistance mutations. Demand is driven by the high prevalence of EGFR mutations in NSCLC, particularly in Asian populations, and the shift toward personalized treatment over conventional chemotherapy. Key players include AstraZeneca, Roche, and Boehringer Ingelheim, with ongoing R&D focused on improving efficacy and addressing acquired resistance. Pricing, reimbursement policies, and competition from immuno-oncology agents like PD-1/PD-L1 inhibitors influence market dynamics. Emerging markets in Asia-Pacific show rapid growth due to increasing diagnosis rates and healthcare investment, while North America and Europe remain dominant in innovation and adoption.
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market size was estimated at USD 6439.0 million in 2024, exhibiting a CAGR of 8.50% during the forecast period.
This report provides a deep insight into the global Targeted Drug EGFR RTK Inhibitors for NSCLC market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drug EGFR RTK Inhibitors for NSCLC market in any manner.
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Market Segmentation (by Type)
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Others
Market Segmentation (by Application)
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market
Overview of the regional outlook of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Targeted Drug EGFR RTK Inhibitors for NSCLC, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
192 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Targeted Drug EGFR RTK Inhibitors for NSCLC
- 1.2 Key Market Segments
- 1.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
- 1.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) Estimates and Forecasts (2020-2033)
- 2.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Estimates and Forecasts (2020-2033)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Product Life Cycle
- 3.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Manufacturers (2020-2025)
- 3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competitive Situation and Trends
- 3.8.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Chain Analysis
- 4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Targeted Drug EGFR RTK Inhibitors for NSCLC Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Targeted Drug EGFR RTK Inhibitors for NSCLC Market
- 5.7 ESG Ratings of Leading Companies
- 6 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2020-2025)
- 6.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
- 6.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Price by Type (2020-2025)
- 7 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Sales by Application (2020-2025)
- 7.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) by Application (2020-2025)
- 7.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Growth Rate by Application (2020-2025)
- 8 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Sales by Region
- 8.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
- 8.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
- 8.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Region
- 8.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
- 8.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
- 8.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region
- 8.3 North America
- 8.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
- 8.3.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
- 8.4.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
- 8.5.2 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
- 8.6.2 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
- 8.7.2 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Production by Region
- 9.1 Global Production of Targeted Drug EGFR RTK Inhibitors for NSCLC by Region(2020-2025)
- 9.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region (2020-2025)
- 9.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production
- 9.4.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
- 9.4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production
- 9.5.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
- 9.5.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production (2020-2025)
- 9.6.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
- 9.6.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production (2020-2025)
- 9.7.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
- 9.7.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Beta Pharma
- 10.1.1 Beta Pharma Basic Information
- 10.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.1.4 Beta Pharma Business Overview
- 10.1.5 Beta Pharma SWOT Analysis
- 10.1.6 Beta Pharma Recent Developments
- 10.2 AstraZeneca
- 10.2.1 AstraZeneca Basic Information
- 10.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.2.4 AstraZeneca Business Overview
- 10.2.5 AstraZeneca SWOT Analysis
- 10.2.6 AstraZeneca Recent Developments
- 10.3 Natco Pharma
- 10.3.1 Natco Pharma Basic Information
- 10.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.3.4 Natco Pharma Business Overview
- 10.3.5 Natco Pharma SWOT Analysis
- 10.3.6 Natco Pharma Recent Developments
- 10.4 Qilu Pharmaceutical
- 10.4.1 Qilu Pharmaceutical Basic Information
- 10.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.4.4 Qilu Pharmaceutical Business Overview
- 10.4.5 Qilu Pharmaceutical Recent Developments
- 10.5 Genentech (Roche Group)
- 10.5.1 Genentech (Roche Group) Basic Information
- 10.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.5.4 Genentech (Roche Group) Business Overview
- 10.5.5 Genentech (Roche Group) Recent Developments
- 10.6 Mylan
- 10.6.1 Mylan Basic Information
- 10.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.6.4 Mylan Business Overview
- 10.6.5 Mylan Recent Developments
- 10.7 Teva
- 10.7.1 Teva Basic Information
- 10.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.7.4 Teva Business Overview
- 10.7.5 Teva Recent Developments
- 10.8 OSI Pharmaceuticals
- 10.8.1 OSI Pharmaceuticals Basic Information
- 10.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.8.4 OSI Pharmaceuticals Business Overview
- 10.8.5 OSI Pharmaceuticals Recent Developments
- 10.9 Glenmark Pharmaceuticals
- 10.9.1 Glenmark Pharmaceuticals Basic Information
- 10.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.9.4 Glenmark Pharmaceuticals Business Overview
- 10.9.5 Glenmark Pharmaceuticals Recent Developments
- 10.10 Beacon Pharmaceuticals
- 10.10.1 Beacon Pharmaceuticals Basic Information
- 10.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.10.4 Beacon Pharmaceuticals Business Overview
- 10.10.5 Beacon Pharmaceuticals Recent Developments
- 10.11 Boehringer Ingelheim
- 10.11.1 Boehringer Ingelheim Basic Information
- 10.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.11.4 Boehringer Ingelheim Business Overview
- 10.11.5 Boehringer Ingelheim Recent Developments
- 10.12 Pfizer
- 10.12.1 Pfizer Basic Information
- 10.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.12.4 Pfizer Business Overview
- 10.12.5 Pfizer Recent Developments
- 10.13 ARIAD Pharmaceuticals (Takeda)
- 10.13.1 ARIAD Pharmaceuticals (Takeda) Basic Information
- 10.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.13.4 ARIAD Pharmaceuticals (Takeda) Business Overview
- 10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
- 10.14 Genvio Pharma Limited
- 10.14.1 Genvio Pharma Limited Basic Information
- 10.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.14.4 Genvio Pharma Limited Business Overview
- 10.14.5 Genvio Pharma Limited Recent Developments
- 10.15 Drug International Limted
- 10.15.1 Drug International Limted Basic Information
- 10.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.15.4 Drug International Limted Business Overview
- 10.15.5 Drug International Limted Recent Developments
- 10.16 Everest Pharmaceuticals
- 10.16.1 Everest Pharmaceuticals Basic Information
- 10.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.16.4 Everest Pharmaceuticals Business Overview
- 10.16.5 Everest Pharmaceuticals Recent Developments
- 10.17 Incepta Pharmaceuticals Limited
- 10.17.1 Incepta Pharmaceuticals Limited Basic Information
- 10.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.17.4 Incepta Pharmaceuticals Limited Business Overview
- 10.17.5 Incepta Pharmaceuticals Limited Recent Developments
- 10.18 Cipla Pharma
- 10.18.1 Cipla Pharma Basic Information
- 10.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.18.4 Cipla Pharma Business Overview
- 10.18.5 Cipla Pharma Recent Developments
- 10.19 Dr Reddy's Laboratories
- 10.19.1 Dr Reddy's Laboratories Basic Information
- 10.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.19.4 Dr Reddy's Laboratories Business Overview
- 10.19.5 Dr Reddy's Laboratories Recent Developments
- 10.20 Zydus Cadila
- 10.20.1 Zydus Cadila Basic Information
- 10.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.20.4 Zydus Cadila Business Overview
- 10.20.5 Zydus Cadila Recent Developments
- 10.21 Hetero Drugs
- 10.21.1 Hetero Drugs Basic Information
- 10.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.21.4 Hetero Drugs Business Overview
- 10.21.5 Hetero Drugs Recent Developments
- 10.22 Intas Pharmaceuticals
- 10.22.1 Intas Pharmaceuticals Basic Information
- 10.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.22.4 Intas Pharmaceuticals Business Overview
- 10.22.5 Intas Pharmaceuticals Recent Developments
- 10.23 Alkem Laboratories
- 10.23.1 Alkem Laboratories Basic Information
- 10.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.23.4 Alkem Laboratories Business Overview
- 10.23.5 Alkem Laboratories Recent Developments
- 10.24 RPG Life Sciences
- 10.24.1 RPG Life Sciences Basic Information
- 10.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.24.4 RPG Life Sciences Business Overview
- 10.24.5 RPG Life Sciences Recent Developments
- 10.25 Fresenius Kabi India
- 10.25.1 Fresenius Kabi India Basic Information
- 10.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
- 10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
- 10.25.4 Fresenius Kabi India Business Overview
- 10.25.5 Fresenius Kabi India Recent Developments
- 11 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Region
- 11.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast
- 11.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
- 11.2.3 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region
- 11.2.4 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Targeted Drug EGFR RTK Inhibitors for NSCLC by Country
- 12 Forecast Market by Type and by Application (2026-2033)
- 12.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Type (2026-2033)
- 12.1.1 Global Forecasted Sales of Targeted Drug EGFR RTK Inhibitors for NSCLC by Type (2026-2033)
- 12.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2026-2033)
- 12.1.3 Global Forecasted Price of Targeted Drug EGFR RTK Inhibitors for NSCLC by Type (2026-2033)
- 12.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Application (2026-2033)
- 12.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales (K Units) Forecast by Application
- 12.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) Forecast by Application (2026-2033)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
